<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EFC213B-0A26-4B81-90CA-8F67F26F8FD5"><gtr:id>3EFC213B-0A26-4B81-90CA-8F67F26F8FD5</gtr:id><gtr:name>University of the Basque Country</gtr:name><gtr:address><gtr:line1>Barrio Sarriena s/n</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EFC213B-0A26-4B81-90CA-8F67F26F8FD5"><gtr:id>3EFC213B-0A26-4B81-90CA-8F67F26F8FD5</gtr:id><gtr:name>University of the Basque Country</gtr:name><gtr:address><gtr:line1>Barrio Sarriena s/n</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9F8F75E8-87B5-4842-975A-FEF86EB86988"><gtr:id>9F8F75E8-87B5-4842-975A-FEF86EB86988</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Wade-Martins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FP007058%2F1"><gtr:id>E4D7A6DC-3483-4993-9464-2F509B6B2E28</gtr:id><gtr:title>Protection of neurons in vitro and in vivo from Synuclein toxicity by molecular tweezers</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/P007058/1</gtr:grantReference><gtr:abstractText>Parkinson's disease is an age-related neurodegenerative disorder in which aggregated clumps of a protein termed alpha-synuclein form in neurons, the cells in the brain which relay electrical information. These clumps are the defining key hallmark pathology of Parkinson's and are called Lewy bodies (LB). In a related disease, multiple system atrophy (MSA), the protein clumps form in the support cells, called glia. The diseases are therefore related and may benefit from a therapy to prevent the formation and spread of alpha-synuclein protein clumps. 

The development of therapeutic strategies to prevent the formation and spread of alpha-synuclein protein clumps and prevent cell death in Parkinson's and MSA has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence demonstrates the importance of the alpha-synuclein clumps in disease pathology and has led to consider the therapeutic potential of several strategies aimed at reducing the burden and toxicity of alpha-synuclein accumulation. Our objective here is to build upon the unique experimental models of disease and complementary expertise of the Consortium. Members of the research team specialise in working in brain cells from mice, and with human neurons derived from stem cells made from Parkinson's patients. Others members of the team work on animal models of Parkinson's and MSA which model how alpha-synuclein may spread in the brain. We will use these models in laboratories in France and in the UK to test a novel molecular therapy called &amp;quot;molecular tweezer&amp;quot; drug which has been shown to inhibit aggregation and toxicity of other similar proteins which clump in other diseases. The drug may therefore protect neurons grown in the laboratory and neurons in the brain from Parkinson's or MSA-associated cell death. By probing the mechanisms and application of &amp;quot;molecular tweezers&amp;quot; to Parkinson's and MSA the project will demonstrate the use or not of such a therapy to prevent alpha-synuclein-mediated cell death.</gtr:abstractText><gtr:technicalSummary>Parkinson disease (PD) is hallmarked by the deposition of aggregated alpha-synuclein (alpha-syn) species into intra-neuronal Lewy bodies (LB) and Lewy neurites (LN) inclusions while in multiple system atrophy (MSA) alpha-syn aggregates form oligodendroglial inclusions. The development of therapeutic strategies to block cell death in PD and MSA has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence of multiple pivotal roles of alpha-syn in the pathogenesis of PD and MSA has led to consider the therapeutic potential of several strategies aimed at reducing alpha-synuclein toxicity. Our objective is to build upon the unique experimental cell (Primary rodent neurons and glial cells - Human neurons derived from PD patients) and animal models of PD (SNCAOVX transgenic mouse and human PD-derived alpha-syn seed-injected mouse) and MSA (PLP-SYN transgenic mouse and human MSA-derived alpha-syn seed-injected mouse), developed by this consortium, for testing whether the prototypical molecular tweezer CLR01, shown to inhibit aggregation and toxicity of other amyloidogenic proteins, could protect neurons in vitro and in vivo from PD / MSA-associated synaptotoxicity and reduce PD and MSA's disease-like alpha-syn pathology. The project will thus (in)validate the molecular tweezers CLR01 for PD and/or MSA indications.</gtr:technicalSummary><gtr:potentialImpactText>The project will foster the development of disease-modifying treatment. To this end, it will develop and characterize a novel innovative molecule (CLR01) in clinically relevant human patient-derived dopaminergic neurons and in novel animal models to study its ability to interfere with alpha-syn pathology that it is induced by increased expression or by pathophysiological spread of patient-derived alpha-syn assemblies. 

The synergy between the three complementary laboratories will maximize the potential for achieving these goals. We will efficiently share and transfer key materials, protocols and data between our laboratories, raising the chances of yielding synergistic, interdisciplinary, and groundbreaking research results. Hence, the outcome will be more than the arithmetic sum of each of our respective expertise, working force and the respective local academic environments. The multidisciplinary aspect of the project is essential to its objectives. It will benefit from expertise in many disciplines within neuroscience, delineating a clear synergistic network of competencies. Not only are different complementary capabilities needed to succeed, but a truly synergistic framework is mandatory. Our newly established links will allow implementing an innovative way of synergic work. The immediate potential impact on both academic and industrial research domains aiming at developing neuroprotective treatments justifies accepting this challenge, as success of this grant would increase Europe competitiveness in an area of neuroscience and neurology which is under high demand and expectation for newer and more efficacious therapeutic approaches.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>145207</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of the Basque Country</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>COEN Group on Parkinson's</gtr:description><gtr:id>4E8FBB36-C4F3-4A5B-A0EA-0B702549C504</gtr:id><gtr:impact>No outputs yet as collaboration is still new.</gtr:impact><gtr:outcomeId>58c92de17b15c3.63262229-2</gtr:outcomeId><gtr:partnerContribution>The University of the Basque Country has provided expertise on advanced microfluidics cell culture. Bordeaux has provided brain extract from Parkinson's patients and the potential therapic compound CLR01.</gtr:partnerContribution><gtr:piContribution>We have contributed Parkinson's derived patient-derived stem cells and neurons. We have then used materials and expertise provided by other partners in our patient neuron cultures.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>COEN Group on Parkinson's</gtr:description><gtr:id>21E0CC42-AD57-414F-9775-4CB604F693C6</gtr:id><gtr:impact>No outputs yet as collaboration is still new.</gtr:impact><gtr:outcomeId>58c92de17b15c3.63262229-1</gtr:outcomeId><gtr:partnerContribution>The University of the Basque Country has provided expertise on advanced microfluidics cell culture. Bordeaux has provided brain extract from Parkinson's patients and the potential therapic compound CLR01.</gtr:partnerContribution><gtr:piContribution>We have contributed Parkinson's derived patient-derived stem cells and neurons. We have then used materials and expertise provided by other partners in our patient neuron cultures.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford PD UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AC82EC4B-106B-447B-A557-73009163F447</gtr:id><gtr:impact>I spoke at a meeting of the Oxford Parkinson's UK branch</gtr:impact><gtr:outcomeId>58891cef147c06.34422019</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford PD UK Carol Service and walk 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BBF416F9-6579-4681-963D-27EE3150D181</gtr:id><gtr:impact>Attended and supported Parkinson's UK Oxford Carol service and sponsored walk 2016</gtr:impact><gtr:outcomeId>58891d6a667799.68061528</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>OPDC Open Day 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EEC5BB88-502B-42E1-90F0-44FC00D425E7</gtr:id><gtr:impact>OPDC Open Day 2016
250 OPDC study Participants and Partners registered for event. 
Day of talks from Michele Hu, Fahd Baig, Claudio Ruffmann, Tom Barber and Richard Wade-Martins. 
Discussion of what participants would like from study.
Talks filmed and podcasts added to website</gtr:impact><gtr:outcomeId>5874d331903c21.75233812</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:url>http://www.opdc.ox.ac.uk/openday2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK walk</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>56F7BB66-74FE-4F0F-87DC-8CA20F90B95C</gtr:id><gtr:impact>Went on a sponsored walk

Raised money and awareness</gtr:impact><gtr:outcomeId>56982685b74895.89745110</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have optimised the methodology for delivery of the potential therapeutic CLR01 in vivo usoing osmotic mini-pumps.</gtr:description><gtr:id>C1BFF244-06B0-48D5-8EB6-8F0E1B9901FB</gtr:id><gtr:impact>Pilot data suggest that CLR01 in vivo may reduce a-syn oligomer burden</gtr:impact><gtr:outcomeId>58c930501e15d7.79547022</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Osmotic mini-pump implantation</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>To enable the detection of a-syn oligomers in stem cell-derived dopamine neurons</gtr:description><gtr:id>EA1EAD00-D855-4A18-B583-A621B6B89033</gtr:id><gtr:impact>The detection of a-syn oligomers in stem cell-derived dopamine neurons</gtr:impact><gtr:outcomeId>58c92f226e65b1.71774930</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PLA in stem cell neurons</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of stem cell-derived neuronal culture techniques using microfluidic devices to channel axonal growth.</gtr:description><gtr:id>EC0E1F10-B25C-4E54-B797-82925603F227</gtr:id><gtr:impact>Not yet: it is ongoing development</gtr:impact><gtr:outcomeId>58c92fc5c46df9.80731551</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Dopamine neuron microfluidics</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1BD2925C-C0E2-405B-AF15-99862F50897D</gtr:id><gtr:title>Loss of MicroRNA-7 Regulation Leads to a-Synuclein Accumulation and Dopaminergic Neuronal Loss In&amp;nbsp;Vivo.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2eb76693ef9c2f39f627c3d99426bb6"><gtr:id>c2eb76693ef9c2f39f627c3d99426bb6</gtr:id><gtr:otherNames>McMillan KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5a53828687b607.08930399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F6B96B1-60F8-4BFC-9DBD-145E5C58C2D9</gtr:id><gtr:title>Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ae016a4386b51a67493edfa71ea497"><gtr:id>58ae016a4386b51a67493edfa71ea497</gtr:id><gtr:otherNames>Doucet M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a5382874d7088.38112834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56C0C82F-2107-48BC-B9B3-855B5B0AA23B</gtr:id><gtr:title>The stem cell cocktail: neural reprogramming just got easier.</gtr:title><gtr:parentPublicationTitle>Stem cell investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77386e2d1342c9dc4a2a7cd878dee12d"><gtr:id>77386e2d1342c9dc4a2a7cd878dee12d</gtr:id><gtr:otherNames>Bengoa-Vergniory N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2306-9759</gtr:issn><gtr:outcomeId>5aa6b3269c0cb1.38948409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24F1D2F8-C3E3-4DCF-9A5E-9138B3DED69B</gtr:id><gtr:title>Identification of Noncanonical Wnt Receptors Required for Wnt-3a-Induced Early Differentiation of Human Neural Stem Cells.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77386e2d1342c9dc4a2a7cd878dee12d"><gtr:id>77386e2d1342c9dc4a2a7cd878dee12d</gtr:id><gtr:otherNames>Bengoa-Vergniory N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>5aa6b3277605f3.47789883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>634AC02C-BC3C-424C-BB96-F1743739A1A0</gtr:id><gtr:title>Alpha-synuclein oligomers: a new hope.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77386e2d1342c9dc4a2a7cd878dee12d"><gtr:id>77386e2d1342c9dc4a2a7cd878dee12d</gtr:id><gtr:otherNames>Bengoa-Vergniory N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5a538286e0a1c1.86627966</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/P007058/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>